Eltrombopag và Dexamethasone liều cao như liệu pháp đầu tay điều trị bệnh tiểu cầu miễn dịch mới được chẩn đoán ở người lớn

Toltl, 2011, Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters., Br J Haematol, 152, 52, 10.1111/j.1365-2141.2010.08412.x Rodeghiero, 2009, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group., Blood, 113, 2386, 10.1182/blood-2008-07-162503 Provan, 2010, International consensus report on the investigation and management of primary immune thrombocytopenia., Blood, 115, 168, 10.1182/blood-2009-06-225565 Cheng, 2003, Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone., N Engl J Med, 349, 831, 10.1056/NEJMoa030254 Matzdorff, 2011, Advances in ITP—therapy and quality of life—a patient survey., PLoS ONE, 6, e27350, 10.1371/journal.pone.0027350 Kuter, 2012, Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care., Am J Hematol, 87, 558, 10.1002/ajh.23163 Zaja, 2010, Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia., Blood, 115, 2755, 10.1182/blood-2009-07-229815 Li, 2011, Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia., Int J Hematol, 93, 91, 10.1007/s12185-010-0753-z Gómez-Almaguer, 2013, High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia., Eur J Haematol, 90, 494, 10.1111/ejh.12102 Gudbrandsdottir, 2013, Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia., Blood, 121, 1976, 10.1182/blood-2012-09-455691 Cheng, 2011, Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study., Lancet, 377, 393, 10.1016/S0140-6736(10)60959-2 Saleh, 2013, Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study., Blood, 121, 537, 10.1182/blood-2012-04-425512 Bussel, 2013, Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)., Br J Haematol, 160, 538, 10.1111/bjh.12169 Neunert, 2011, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia., Blood, 117, 4190, 10.1182/blood-2010-08-302984 Rodeghiero, 2013, Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group., Blood, 121, 2596, 10.1182/blood-2012-07-442392 Kashiwagi, 2013, Pathophysiology and management of primary immune thrombocytopenia., Int J Hematol, 98, 24, 10.1007/s12185-013-1370-4 Bao, 2010, Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents., Blood, 116, 4639, 10.1182/blood-2010-04-281717 Ghadaki, 2013, Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists., Transfusion, 53, 2807, 10.1111/trf.12139 Rao, 2013, ITP: hematology’s Cosette from Les Misérables., Blood, 121, 1928, 10.1182/blood-2013-01-477729 Kühne, 2011, Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group., Haematologica, 96, 1831, 10.3324/haematol.2011.050799